Jingxin Pharmaceutical significantly boosts share repurchase program

Zhejiang Jingxin Pharmaceutical Co., Ltd. (Jingxin Pharmaceutical) announced significant progress in its share repurchase program, with a notable increase in the total repurchased amount. As of November 30, 2025, the company had repurchased 47,271,295 shares through its dedicated securities account via centralized bidding. This represents 5.49% of the company's current total share capital. The highest price paid for a share was RMB14.41, and the lowest was RMB11.86, with the total transaction amount reaching RMB608,722,200 (excluding transaction fees). The repurchase was funded by the company's own funds and adhered to the maximum price of RMB14.47 per share.

The initial repurchase plan, approved on January 8, 2025, intended to repurchase shares valued between RMB200,000,000 and RMB400,000,000. However, on March 7, 2025, the company revised the plan, increasing the total repurchase amount to a range of RMB350,000,000 to RMB700,000,000. Following a rights issue in 2024, the maximum repurchase price was adjusted from RMB14.80 to RMB14.47 per share, effective May 29, 2025.

The repurchased shares are intended for equity incentives or employee stock ownership plans, aligning with the company's strategic goals to enhance internal motivation. Jingxin Pharmaceutical confirmed that the repurchase activities comply with relevant laws and regulations, and the company will continue to disclose information as required, urging investors to be aware of potential investment risks.